Roche to initiate Phase III study to expand access to ElevidysTM, the first approved gene therapy for Duchenne muscular dystrophy.

Unfortunately, it is not yet clear whether Switzerland will take part in this study.

• Elevidys™ has demonstrated the ability to slow progression of Duchenne muscular dystrophy
• New registration-enabling study builds on six years of clinical evidence and feedback from the European Medicines Agency and the Duchenne community
• Goal is to provide a pathway for regulatory submission and broad patient access in Europe and other regions

See press release here.